TSND-201 treatment for PTSD in adults
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
Run by Transcend Therapeutics · NCT07836647 · Data updated 2026-11-12
This study tests two doses of TSND-201 or placebo to see if it helps adults with PTSD.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Transcend Therapeutics Industry-sponsored |
| Locations | 9 sites (Denver, Colorado and 8 other locations) |
| Status | Recruiting |
| Started | September 25, 2026 |
| Main results expected | February 2028 |
| Study ends | February 2028 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT07836647 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a current PTSD diagnosis of at least 6 months who have tried another pharmacologic treatment or trauma-focused therapy and can participate in study interviews and questionnaires.
✕Probably not a fit
Participants who do not respond to TSND-201 or those with exclusionary health conditions may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 3 trial enrolls adults with PTSD who have tried other treatments. Participants are randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, administered weekly during a 4-week treatment period, followed by an 8-week follow-up. The study assesses safety and how well TSND-201 works for reducing PTSD symptoms. Key assessments include interviews and questionnaires to monitor response and adverse effects. Locations include sites in Colorado and Florida, sponsored by Transcend Therapeutics.
Why it matters
Potential benefit: If successful, TSND-201 could reduce PTSD symptoms and improve daily functioning for adults with PTSD.
How similar studies have gone: Previous research in related neuroplastogen approaches has shown promise, but this exact TSND-201 strategy is novel in PTSD.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meets DSM-5 criteria for current PTSD diagnosis, with a symptom duration of at least 6 months. * Tried at least one pharmacological treatment for PTSD or trauma-focused psychotherapy. * Proficient in communication (verbal and reading) to complete interviews and written questionnaires. * Free from any other clinically significant illness or disease. Exclusion Criteria: * Primary diagnosis of any other DSM-5 disorder. * Body mass index (BMI) \<18kg/m2 or ≥40 kg/m2. * Unable to refrain from nicotine use for at least 8 hours. * Use of prohibited concomitant medications or therapies. * Current or previous history of clinically significant cardiovascular (including current uncontrolled hypertension) / cerebrovascular conditions.
Where it's running
-
Mountain View Clinical Research
Denver, Colorado, United States Recruiting -
Bradenton Research Center
Bradenton, Florida, United States Recruiting -
CNS Healthcare
Orlando, Florida, United States Recruiting -
CenExel Tampa
Tampa, Florida, United States Recruiting -
K2 Medical Research Tampa
Tampa, Florida, United States Recruiting -
CenExel Atlanta
Atlanta, Georgia, United States Recruiting
Show 3 more locations
-
CenExel Marlton
Marlton, New Jersey, United States Recruiting -
Bio Behavioral Health
Toms River, New Jersey, United States Recruiting -
Cedar Clinical Research
Draper, Utah, United States Recruiting
Study contacts
- Study coordinator: Study Director
- Email: amanda@transcendtherapeutics.com
- Phone: 650-769-6472
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Anger, Social Thinking, and PTSD in French Veterans
This study tests whether PTSD in former French military personnel is linked to higher anger through changes in social thinking abilities.
-
Long-term outcomes after Hyperbaric Oxygen Therapy in veterans with TBI, PCS, or PTSD
This study tests whether benefits from HBOT persist over time for veterans with brain injury or related conditions.
-
SEE FAR CBT for Adults With PTSD
This 12-week, one-on-one SEE FAR CBT program tests a trauma-focused therapy to see if PTSD symptoms improve in adults 18 and older.
-
Brief SEE FAR CBT: a short, focused therapy for adults with PTSD
A 6-session Brief SEE FAR CBT treatment is tested against usual dynamic psychotherapy for adults with PTSD to see if it reduces symptoms.
-
MDMA Therapy for PTSD in Veterans
This phase 2 study tests a fixed 120 mg dose of MDMA, followed by a 60 mg supplemental dose, plus therapy, to see if it helps adults who are veterans with PTSD.
-
Predicting childbirth PTSD after unplanned cesarean using early postpartum screening
This study tests whether brief postpartum questionnaires taken 24-48 hours after delivery can predict childbirth-related PTSD symptoms at 6 weeks in people who had an unplanned cesarean.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.